-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KvFPNIg4FJFeYAChfJWZUmooQU9BN0nYJXIxOO5oq9dVF037MMkkZEL7cftbNfz0 rJyYEts4hk31DTg3Le5J2A== 0001019687-04-000412.txt : 20040227 0001019687-04-000412.hdr.sgml : 20040227 20040227151634 ACCESSION NUMBER: 0001019687-04-000412 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20040227 ITEM INFORMATION: ITEM INFORMATION: Other events FILED AS OF DATE: 20040227 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SIMULATIONS PLUS INC CENTRAL INDEX KEY: 0001023459 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER INTEGRATED SYSTEMS DESIGN [7373] IRS NUMBER: 954595609 FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-05600-LA FILM NUMBER: 04634828 BUSINESS ADDRESS: STREET 1: 1220 W. AVENUE J STREET 2: * CITY: LANCASTER STATE: CA ZIP: 93534-2902 BUSINESS PHONE: 661-723-7723 MAIL ADDRESS: STREET 1: 1220 W. AVENUE J STREET 2: * CITY: LANCASTER STATE: CA ZIP: 93534-2902 8-K 1 simulations_8k-022704.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 February 27, 2004 ----------------- (Date of the earliest event reported) Simulations Plus, Inc. ---------------------- (Exact name of Registrant as specified in its charter) California 0-21665 95-4595609 ---------- ------- ---------- (State or other jurisdiction (Commission File Number) (I.R.S. Employer of incorporation) Identification No.) 1220 West Avenue J, Lancaster, California 93534 ----------------------------------------------- (Address of principal executive offices) (Zip Code) (661) 723-7723 -------------- Registrant's telephone number, including area code 1 ITEM 5. OTHER EVENTS. On February 27, 2004, Simulations Plus, Inc., a California corporation (the "Company") issued a press release announcing that a global pharmaceutical company has signed a multi-year global software license agreement. ITEM 13. EXHIBITS AND REPORTS ON FORM 8-K. (a) Exhibits 99.1 Press release dated February 27, 2004 2 Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SIMULATIONS PLUS, INC. Dated: February 27, 2004 By: /s/ Momoko Beran ------------------------ Momoko A. Beran Chief Financial Officer 3 EXHIBITS INDEX -------------- Exhibit Number Description -------------- ----------- 99.1 Press release, dated February 27, 2004 4 EX-99.1 3 simulations_8kex99-1.txt EXHIBIT 99.1 SIMULATIONS PLUS ANNOUNCES ANOTHER MULTI-YEAR PHARMACEUTICAL SOFTWARE LICENSE SALE CONTRIBUTES TO NEW RECORD FOR SECOND FISCAL QUARTER REVENUES LANCASTER, CA, FEBRUARY 27, 2004. Simulations Plus, Inc. (OTCBB: SIMU), the leading provider of ADME absorption simulation and neural net structure-to-property prediction software for pharmaceutical discovery and development, today announced that a global pharmaceutical company has signed a multi-year global software license agreement. The first multi-year global license by a large pharmaceutical company was announced by the Company in the fourth quarter of its previous fiscal year in August 2003. Neither customer has agreed to be identified. Ron Creeley, vice president of marketing and sales for Simulations Plus and the company's Words+ subsidiary, said, "We're pleased to announce another multi-year license agreement for Simulations Plus software. Because this two-year license covers only a portion of our software offerings for the customer's multiple research sites, we believe that we still have the opportunity to license additional software to this customer during the two-year period. As we have noted earlier, we continue to pursue multi-year global license agreements with other large pharmaceutical customers as one part of our growth strategy." Momoko Beran, chief financial officer for Simulations Plus, added, "This license, added to our other pharmaceutical software license sales for the quarter, as well as improved sales for our Words+ subsidiary over last year's second quarter, is expected to result in another record for second quarter revenues. Preliminary figures indicate an increase in revenues of approximately 18% over last year's second quarter." The Company's second fiscal quarter ends on February 29. ABOUT SIMULATIONS PLUS, INC. Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. The Company has two other businesses, Words+, Inc. and FutureLab(TM), which are based on its proprietary software technologies. Simulations Plus, Inc., is headquartered in Southern California and trades on the OTCBB under the symbol "SIMU." For more information, visit our Web site at www.simulations-plus.com. SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 - - With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of the Company could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: the ability of the Company to book revenues and earnings as it expects for the current quarter, the ability of the Company to maintain its competitive advantage, the general economics of the pharmaceutical industry, the ability of the Company to attract and retain sufficient scientific and technical staff to sustain its R&D and customer support functions, and a sustainable market. Further information on the Company's risk factors is contained in the Company's quarterly and annual reports as filed with the Securities and Exchange Commission. ### 5 -----END PRIVACY-ENHANCED MESSAGE-----